KR20220160040A - T 세포 수용체 - Google Patents

T 세포 수용체 Download PDF

Info

Publication number
KR20220160040A
KR20220160040A KR1020227036819A KR20227036819A KR20220160040A KR 20220160040 A KR20220160040 A KR 20220160040A KR 1020227036819 A KR1020227036819 A KR 1020227036819A KR 20227036819 A KR20227036819 A KR 20227036819A KR 20220160040 A KR20220160040 A KR 20220160040A
Authority
KR
South Korea
Prior art keywords
amino acid
leu
ser
tcr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227036819A
Other languages
English (en)
Korean (ko)
Inventor
자스딥 만
Original Assignee
2세븐티 바이오, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 2세븐티 바이오, 인코포레이티드 filed Critical 2세븐티 바이오, 인코포레이티드
Publication of KR20220160040A publication Critical patent/KR20220160040A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227036819A 2020-03-27 2021-03-26 T 세포 수용체 Pending KR20220160040A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000800P 2020-03-27 2020-03-27
US63/000,800 2020-03-27
PCT/US2021/024370 WO2021195503A1 (en) 2020-03-27 2021-03-26 T cell receptors

Publications (1)

Publication Number Publication Date
KR20220160040A true KR20220160040A (ko) 2022-12-05

Family

ID=77890524

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227036819A Pending KR20220160040A (ko) 2020-03-27 2021-03-26 T 세포 수용체

Country Status (11)

Country Link
US (1) US20230124640A1 (https=)
EP (1) EP4126924A4 (https=)
JP (2) JP7738007B2 (https=)
KR (1) KR20220160040A (https=)
CN (1) CN115485294A (https=)
AU (1) AU2021244594A1 (https=)
BR (1) BR112022019380A2 (https=)
CA (1) CA3177181A1 (https=)
IL (1) IL296827A (https=)
MX (1) MX2022012062A (https=)
WO (1) WO2021195503A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3225252A1 (en) 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies
CN119546328A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物
CN117003855B (zh) * 2023-09-20 2024-02-23 广州市老人院 一种t细胞受体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8361794B2 (en) * 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
LT3424947T (lt) * 2011-10-28 2021-03-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos t ląstelių receptorių pelės
CN102876715B (zh) 2012-09-05 2014-07-23 南方医科大学 一种用于结核/hiv共感染基因治疗的逆转录病毒载体及其应用
CN102911267B (zh) 2012-09-19 2014-04-02 南方医科大学 一种结核/hiv抗原肽双特异性tcr、其重组逆转录病毒载体与应用
EP3472208B9 (en) 2016-06-17 2023-10-04 Medigene Immunotherapies GmbH T cell receptors and uses thereof
CN110352068A (zh) * 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
BR112020006643A2 (pt) * 2017-10-03 2020-09-24 Juno Therapeutics Inc moléculas de ligação específica ao hpv
EP3714941A1 (en) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
KR20220030933A (ko) 2019-05-08 2022-03-11 메디진 이뮤노테라피스 게엠바하 조작된 t 세포
CA3225252A1 (en) * 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies

Also Published As

Publication number Publication date
IL296827A (en) 2022-11-01
CN115485294A (zh) 2022-12-16
CA3177181A1 (en) 2021-09-30
BR112022019380A2 (pt) 2022-11-29
JP2025172113A (ja) 2025-11-20
EP4126924A1 (en) 2023-02-08
EP4126924A4 (en) 2024-04-24
JP7738007B2 (ja) 2025-09-11
JP2023519868A (ja) 2023-05-15
AU2021244594A1 (en) 2022-12-01
US20230124640A1 (en) 2023-04-20
MX2022012062A (es) 2023-01-11
WO2021195503A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
AU2020267641B2 (en) Engineered T cells
AU2020232597B2 (en) Constitutively active chimeric cytokine receptors
US20190175651A1 (en) Immortalized car-t cells genetically modified to elminate t-cell receptor and beta 2-microglobulin expression
US20210260118A1 (en) Bcma car-t cells with enhanced activities
KR20220033485A (ko) 암을 치료하기 위한 조성물 및 방법
KR20200130826A (ko) 개선된 면역요법을 위한 유전자-조절 조성물 및 방법
JP2025172113A (ja) Ｔ細胞受容体
US20240342215A1 (en) Engineered t cell receptors fused to binding domains from antibodies
KR20230053650A (ko) Bcma 키메라 항원 수용체
JP2021506271A (ja) Ｄａｒｉｃインターロイキン受容体
EP3966338A1 (en) Cd123 targeted immunotherapies
US20230071910A1 (en) Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
CN117987435A (zh) 氧依赖性嵌合抗原受体表达及其应用
EA052725B1 (ru) Т-клеточные рецепторы
WO2022099176A1 (en) Aml targeted immunotherapies
EA049270B1 (ru) Сконструированные т-клетки
JP2025524629A (ja) 組み換えサイトカイン受容体及び使用方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D13 Search requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D13-SRH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902